# Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

> **NCT00127023** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 944 (—)

## Conditions studied

- Mumps
- Varicella
- Rubella
- Measles

## Interventions

- **BIOLOGICAL:** Measles, Mumps, Rubella and Chickenpox (live vaccine)

## Key facts

- **NCT ID:** NCT00127023
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 944 (—)
- **Last updated:** 2016-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00127023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00127023, "Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00127023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*